W
Wayne Langholff
Researcher at Janssen Pharmaceutica
Publications - 51
Citations - 2611
Wayne Langholff is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Psoriasis & Infliximab. The author has an hindex of 18, co-authored 44 publications receiving 2222 citations.
Papers
More filters
Journal ArticleDOI
Serious Infection and Mortality in Patients With Crohn ' s Disease: More Than 5 Years of Follow-Up in the TREAT ™ Registry
Gary R. Lichtenstein,Brian G. Feagan,Russell D. Cohen,Bruce Salzberg,Robert H. Diamond,Samiyeh Price,Wayne Langholff,Anil Londhe,William J. Sandborn +8 more
TL;DR: Mortality was similar between infliximab- and other-treatments-only-treated CD patients, although CD severity and use of prednisone or narcotic analgesics carried higher risks, and an increased risk of serious infection with inflIXimab was observed.
Journal ArticleDOI
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Robert E. Kalb,David Fiorentino,Mark Lebwohl,John Toole,Yves Poulin,Arnon D. Cohen,Kavitha Goyal,Steven Fakharzadeh,S. Calabro,Marc Chevrier,Wayne Langholff,Yin You,Craig L. Leonardi +12 more
TL;DR: Results from PSOLAR suggest a higher risk of serious infections with adalimumab and infliximab compared with nonmethotrexate and nonbiologic therapies.
Journal Article
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kim A. Papp,Alice B. Gottlieb,Luigi Naldi,David M. Pariser,Ho,Goyal K,Fakharzadeh S,Marc Chevrier,Calabro S,Wayne Langholff,Gerald G. Krueger +10 more
TL;DR: Analysis of 2014 PSOLAR data identified no increased risk of malignancy, MACE, serious infection, or mortality with ustekinumab.
Journal ArticleDOI
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Alan Menter,Kim A. Papp,Melinda Gooderham,David M. Pariser,Matthias Augustin,Francisco A. Kerdel,Steven Fakharzadeh,Kavitha Goyal,S. Calabro,Wayne Langholff,S. Chavers,D. Naessens,J. Sermon,Gerald G. Krueger +13 more
TL;DR: Drug survival is a marker for treatment sustainability in chronic diseases such as psoriasis and it is important to know whether the drug is still available for use in the future.
Journal ArticleDOI
Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
Gary R. Lichtenstein,Brian G. Feagan,Russell D. Cohen,Bruce Salzberg,Robert H. Diamond,Wayne Langholff,Anil Londhe,William J. Sandborn +7 more
TL;DR: Age, disease duration, and smoking were independently associated with increased risk of malignancy in the TREAT Registry, and although results for immunosuppressant use were equivocal, no significant association between malignancies and infliximab was observed.